

Richard W Joseph

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/527528/publications.pdf>

Version: 2024-02-01

89
papers

17,370
citations

100601

38
h-index

60403

85
g-index

91
all docs

91
docs citations

91
times ranked

23826
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144. | 13.9 | 3,128 |
| 2 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , 2016, 387, 1909-1920. | 6.3 | 3,077 |
| 3 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , 2017, 389, 67-76. | 6.3 | 1,728 |
| 4 | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet</i> , 2014, 384, 1109-1117. | 6.3 | 1,588 |
| 5 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757. | 15.2 | 900 |
| 6 | Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600. | 3.8 | 857 |
| 7 | Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517. | 0.8 | 627 |
| 8 | <i>NRAS</i> mutation status is an independent prognostic factor in metastatic melanoma. <i>Cancer</i> , 2012, 118, 4014-4023. | 2.0 | 589 |
| 9 | Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4102-4109. | 0.8 | 528 |
| 10 | Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1668-1674. | 0.8 | 360 |
| 11 | High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018, 553, 347-350. | 13.7 | 269 |
| 12 | Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 5329-5340. | 3.2 | 266 |
| 13 | Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967. | 3.2 | 222 |
| 14 | The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354. | | 182 |
| 15 | Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. <i>Molecular Immunology</i> , 2015, 67, 4-17. | 1.0 | 180 |
| 16 | Therapy for metastatic melanoma: the past, present, and future. <i>BMC Medicine</i> , 2012, 10, 23. | 2.3 | 179 |
| 17 | Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. <i>European Journal of Cancer</i> , 2017, 75, 47-55. | 1.3 | 145 |
| 18 | PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. <i>Cancer Immunology Research</i> , 2015, 3, 1303-1307. | 1.6 | 135 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. <i>Cancer</i> , 2014, 120, 1059-1067. | 2.0 | 129 |
| 20 | Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5250-5260. | 3.2 | 116 |
| 21 | Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. <i>Journal of Urology</i> , 2016, 195, 180-187. | 0.2 | 113 |
| 22 | Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 66-72. | 1.2 | 111 |
| 23 | Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2013, 1, 373-377. | 1.6 | 100 |
| 24 | Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2015, 3, 18-22. | 1.6 | 100 |
| 25 | Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81. | | 79 |
| 26 | NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 945-958. | 2.3 | 76 |
| 27 | High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. <i>Oncogene</i> , 2016, 35, 1565-1574. | 2.6 | 72 |
| 28 | Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191. | 1.3 | 57 |
| 29 | Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. <i>Modern Pathology</i> , 2016, 29, 34-42. | 2.9 | 55 |
| 30 | A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. <i>Melanoma Research</i> , 2012, 22, 294-301. | 0.6 | 53 |
| 31 | Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. <i>European Urology</i> , 2017, 71, 979-985. | 0.9 | 52 |
| 32 | Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 4882-4891. | 3.2 | 48 |
| 33 | The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. <i>Frontiers in Oncology</i> , 2017, 7, 121. | 1.3 | 48 |
| 34 | Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients. <i>Surgical Oncology</i> , 2018, 27, 11-17. | 0.8 | 48 |
| 35 | ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma. <i>BMC Urology</i> , 2014, 14, 14. | 0.6 | 47 |
| 36 | Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1-year following surgical treatment for localized prostate cancer. <i>Psycho-Oncology</i> , 2013, 22, 1328-1335. | 1.0 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 23.e9-23.e14. | 0.8 | 40 |
| 38 | Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. <i>European Urology Focus</i> , 2016, 2, 204-209. | 1.6 | 40 |
| 39 | Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2017, 5, 357-362. | 1.6 | 40 |
| 40 | Negative Sentinel Lymph Node Biopsy in Merkel Cell Carcinoma is Associated with a Low Risk of Same-Nodal-Basin Recurrences. <i>Annals of Surgical Oncology</i> , 2015, 22, 4060-4066. | 0.7 | 39 |
| 41 | Steroid hormone influence on melanomagenesis. <i>Molecular and Cellular Endocrinology</i> , 2015, 417, 94-102. | 1.6 | 38 |
| 42 | Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2013, 1, 378-385. | 1.6 | 37 |
| 43 | Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3706-3713. | 0.8 | 34 |
| 44 | Vitamin D receptor upregulation in alloreactive human T cells. <i>Human Immunology</i> , 2012, 73, 693-698. | 1.2 | 33 |
| 45 | Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 352-356. | 2.0 | 33 |
| 46 | Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. <i>Drug Design, Development and Therapy</i> , 2014, 8, 775. | 2.0 | 32 |
| 47 | c-MET expression in primary and liver metastases in uveal melanoma. <i>Melanoma Research</i> , 2014, 24, 617-620. | 0.6 | 30 |
| 48 | Higher Expression of Topoisomerase II Alpha Is an Independent Marker of Increased Risk of Cancer-specific Death in Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2014, 66, 929-935. | 0.9 | 29 |
| 49 | NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma. <i>Cancer</i> , 2018, 124, 537-545. | 2.0 | 27 |
| 50 | Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. <i>PLoS ONE</i> , 2020, 15, e0230306. | 1.1 | 27 |
| 51 | High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2011, 86, 954-956. | 2.0 | 26 |
| 52 | BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. <i>BMC Urology</i> , 2017, 17, 19. | 0.6 | 26 |
| 53 | Age-period-cohort Analysis of Renal Cell Carcinoma in United States Adults. <i>Urology</i> , 2013, 82, 43-47. | 0.5 | 25 |
| 54 | Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1962-1971. | 1.9 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Three Hundred Consecutive Emergent Celiotomies in General Surgery Patients. <i>Annals of Surgery</i> , 2002, 235, 681-689. | 2.1 | 24 |
| 56 | Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2. <i>Journal of Immunotherapy</i> , 2012, 35, 711-715. | 1.2 | 24 |
| 57 | Management of Metastatic Apocrine Hidradenocarcinoma with Chemotherapy and Radiation. <i>Rare Tumors</i> , 2015, 7, 133-135. | 0.3 | 22 |
| 58 | Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma. <i>Frontiers in Oncology</i> , 2018, 8, 71. | 1.3 | 22 |
| 59 | Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass. <i>Journal of Clinical Oncology</i> , 2015, 33, e74-e76. | 0.8 | 20 |
| 60 | Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. <i>Melanoma Research</i> , 2016, 26, 409-412. | 0.6 | 20 |
| 61 | Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. <i>Cancer Immunology Research</i> , 2016, 4, 569-573. | 1.6 | 20 |
| 62 | Patient-derived tumor xenograft models for melanoma drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 895-906. | 2.5 | 20 |
| 63 | Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives. <i>Journal of Kidney Cancer and VHL</i> , 2018, 5, 15-18. | 0.2 | 20 |
| 64 | An Integrated Model of the Transcriptome of HER2-Positive Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e79298. | 1.1 | 18 |
| 65 | Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma. <i>Carcinogenesis</i> , 2014, 35, 822-827. | 1.3 | 18 |
| 66 | Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis. <i>Journal of Translational Medicine</i> , 2016, 14, 198. | 1.8 | 17 |
| 67 | Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. <i>Quality of Life Research</i> , 2020, 29, 2651-2660. | 1.5 | 17 |
| 68 | Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 142-148. | 0.8 | 16 |
| 69 | Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. <i>Journal of Immunotherapy</i> , 2017, 40, 334-340. | 1.2 | 16 |
| 70 | New-onset insulin-dependent diabetes due to nivolumab. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, . | 0.2 | 14 |
| 71 | Desmoplastic melanoma: a brief review and the efficacy of immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 205-207. | 1.1 | 13 |
| 72 | Whole Exome Sequencing of a Patient with Metastatic Hidradenocarcinoma and Review of the Literature. <i>Rare Tumors</i> , 2015, 7, 29-33. | 0.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis1These authors contributed equally to the writing of this article.. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 68.e17-68.e23. | 0.8 | 10 |
| 74 | A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona. PLoS ONE, 2015, 10, e0132831. | 1.1 | 9 |
| 75 | A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 196-202.e1. | 0.9 | 9 |
| 76 | Chronic graft-versus-host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care. The Journal of Supportive Oncology, 2008, 6, 361-72. | 2.3 | 9 |
| 77 | Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma. Rare Tumors, 2017, 9, 50-53. | 0.3 | 8 |
| 78 | Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy. Melanoma Management, 2017, 4, 143-145. | 0.1 | 8 |
| 79 | Ultrathin primary is a marker for worse prognosis in lymph node–positive cutaneous melanoma. Cancer, 2013, 119, 1860-1867. | 2.0 | 7 |
| 80 | Validation of Gene Expression Signatures to Identify Low-risk Clear-cell Renal Cell Carcinoma Patients at Higher Risk for Disease-related Death. European Urology Focus, 2016, 2, 608-615. | 1.6 | 7 |
| 81 | Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers. Journal of Medical Economics, 2020, 23, 132-138. | 1.0 | 6 |
| 82 | Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. PLoS ONE, 2021, 16, e0248097. | 1.1 | 5 |
| 83 | Efficacy of immunotherapy for metastatic mucosal melanoma. Immunotherapy, 2016, 8, 843-845. | 1.0 | 3 |
| 84 | Drug-associated vasculitis occurring after treatment with pembrolizumab. Rheumatology, 2019, 58, 1501-1503. | 0.9 | 3 |
| 85 | Factors associated with immunotherapy selection in patients with advanced melanoma. Immunotherapy, 2018, 10, 1361-1369. | 1.0 | 2 |
| 86 | Title is missing!. , 2020, 15, e0230306. | | 0 |
| 87 | Title is missing!. , 2020, 15, e0230306. | | 0 |
| 88 | Title is missing!. , 2020, 15, e0230306. | | 0 |
| 89 | Title is missing!. , 2020, 15, e0230306. | | 0 |